Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2001-11-02
2004-01-13
Graser, Jennifer E. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
C424S185100, C424S190100, C424S192100, C424S193100, C424S197110, C424S201100, C424S203100, C424S204100, C424S217100, C424S227100, C424S258100, C424S245100, C530S395000
Reexamination Certificate
active
06676945
ABSTRACT:
The Present application is a Divisional Application of U.S. Ser. No. 09/599,366 filed Jun. 21, 2000, now U.S. Pat. No. 6,335,181, which is a Divisional of U.S. application Ser. No. 09/132,528 filed Aug. 11, 1998, now U.S. Pat. No. 6,221,353, which is a divisional of application Ser. No. 08/641,356 filed Apr. 30, 1996, now U.S. Pat. No. 5,866,130, which is a divisional of U.S. Ser. No. 08/382,184 filed Feb. 1, 1995, now U.S. Pat. No. 5,714,593.
The object of the present invention is mycobacterial proteins and microorganisms producing them.
It also relates to the use of these proteins in vaccines or for the detection of
tuberculosis.
Tuberculosis
continues to be a public health problem throughout the world. The annual number of deaths directly related to
tuberculosis
is about 3 million and the number of new cases of
tuberculosis
is about 15 million. This number of deaths due to
tuberculosis
is high even for the developed countries; for example in France it is of the order of 1500 per year, a figure which is certainly underestimated by a factor of 2 or 3 if Roujeau's assessments of the differences between official figures and the results of systematic autopsies are taken into account. The recent increase in
tuberculosis
cases, or at least the levelling-off of the decrease in the frequency of this disease, must be considered in correlation with the development of the HIV/AIDS epidemic. In total,
tuberculosis
remains the leading infectious disease in terms of frequency in France and the developed countries, but above all in the developing countries for which it constitutes the principal source of human loss related to a single disease.
At present, a definite diagnosis made by the demonstration of cultivatable bacilli in a sample taken from the patient is only obtained in less than half the cases of
tuberculosis
. Even for pulmonary
tuberculosis
, which represents 80 to 90% of the
tuberculosis
cases, and which is the form of the disease for which the detection of the bacilli is the easiest, the examination of expectorations is only positive for less than half the cases.
The development of more sensitive techniques such as PCR (amplification by polymerase chain reaction), always comes up against the necessity for obtaining a sample. Women and children do not normally spit, and samples for infants frequently require relatively specialized medical intervention (for example ganglionic biopsy or sampling by lumbar puncture of the cephalorachidian fluid).
In other respects, inhibitions of the PCR reaction itself exist, of a type such that a sample may be unusable by this technique because of the impossibility of controlling its origins.
Finally, because of its limits of sensitivity (at the best of the order of 10
4
to 10
5
bacilli in the sample) the classic bacteriological diagnosis, microscopic examination and culture, requires that there has already been a relatively substantial development of bacilli and thus of the disease.
The detection of specific antibodies directed against
Mycobacterium tuberculosis
should thus be of assistance in the diagnosis of the common forms of the disease for which the detection of the bacilli themselves is difficult or impossible.
Successive generations of research workers have attempted to perfect a serological diagnostic technique for
tuberculosis.
For a general review of studies carried out in this area, the application PCT WO-92/21758 may advantageously be referred to.
The techniques reported in the prior art are thus largely based on the preliminary isolation of proteins through their biochemical properties. It is not until after this isolation that the authors have tested the capacity of these proteins to detect those individuals affected by
tuberculosis.
Application PCT WO-92/21758 describes a method for unambiguously selecting representative antigens of tubercular infection using serums originating from patients affected by
tuberculosis
or guinea-pigs immunized by live bacilli. This method, which is distinguished from the majority of the experiments described in the prior art, has led to the isolation of
M.bovis
proteins with molecular weights between 44.5 and 47.5 kD.
The seventeen amino acids of the N-terminal of one of these proteins were determined and are the following: (SEQ ID NO:5)
ALA-PRO-GLU-PRO-ALA-PRO-PRO-VAL-PRO-PRO-ALA-ALA-
1 2 3 4 5 6 7 8 9 10 11 12
ALA-ALA-PRO-PRO-ALA
15 16 17
The article by ROMAIN et al. (1993, Infection and immunity, 61, 742-750) recapitulates the substance of the results described in this international application. It more particularly describes a competitive ELISA assay using a rabbit polyclonal immune serum obtained by immunizing rabbits against the 45-47 kD protein complex described above.
In parallel, a gene library from
Mycobacterium tuberculosis
has been created by JACOBS et al. (1991, Methods Enzymol., 204, 537-557).
This library contains a large number of different clones.
A protein from another Mycobacteria species,
M. leprae
, has moreover been identified by WIELES et al. (1994, Infection and Immunity, 62, 252-258). This protein, named 43 L, has a molecular weight deduced from the nucleotide sequence of about 25.5 Da. Its N-terminal has 47% homology with that of the 45-47 kDa protein complex identified in
Mycobacterium bovis
BCG, and whose 17 amino acid sequence is given above.
As stated above, there is a major interest in human medicine, as much from the therapeutic as the diagnostic point of view, in accurately identifying the proteins produced by the Mycobacteria and in particular by
M. tuberculosis.
The problem which is in fact posed and is as yet unresolved lies in obtaining vaccines against a large number of diseases.
Another problem lies in the detection of diseases induced by the Mycobacteria, such as
tuberculosis.
The applicant has thus pursued the determination of the sequence of a
Mycobacterium tuberculosis
protein, which is suspected of playing a major role in the immune response.
The applicant has demonstrated that the group of proteins corresponding to the 45-47 kD complex described above is coded by one and the same gene, and that the calculated molecular mass is different from the molecular mass estimated on polyacrylamide gel, because of its richness in proline.
The object of the present invention is thus a protein having at least a portion of one of the following sequences SEQ ID No2 or SEQ ID No3:
SEQ ID No2:
Met His Gln Val Asp Pro Asn Leu Thr Arg Arg Lys Gly Arg Leu Ala Ala Leu Ala lle Ala Ala Met Ala Ser Ala Ser Leu Val Thr Val Ala Val Pro Ala Thr Ala Asn Ala Asp Pro Glu Pro Ala Pro Pro Val Pro Thr Thr Ala Ala Ser Pro Pro Ser Thr Ala Ala Ala Pro Pro Ala Pro Ala Thr Pro Val Ala Pro Pro Pro Pro Ala Ala Ala Asn Thr Pro Asn Ala Gln Pro Gly Asp Pro Asn Ala Ala Pro Pro Pro Ala Asp Pro Asn Ala Pro Pro Pro Pro Val Ile Ala Pro Asn Ala Pro Gln Pro Val Arg Ile Asp Asn Pro Val Gly Gly Phe Ser Phe Ala Leu Pro Ala Gly Trp Val Glu Ser Asp Ala Ala His Phe Asp Tyr Gly Ser Ala Leu Leu Ser Lys Thr Thr Gly Asp Pro Pro Phe Pro Gly Gln Pro Pro Pro Val Ala Asn Asp Thr Arg Ile Val Leu Gly Arg Leu Asp Gln Lys Leu Tyr Ala Ser Ala Glu Ala Thr Asp Ser Lys Ala Ala Ala Arg Leu Gly Ser Asp Met Gly Glu Phe Tyr Met Pro Tyr Pro Gly Thr Arg Ile Asn Gln Glu Thr Val Ser Leu Asp Ala Asn Gly Val Ser Gly Ser Ala Ser Tyr Tyr Glu Val Lys Phe Ser Asp Pro Ser Lys Pro Asn Gly Gln Ile Trp Thr Gly Val Ile Gly Ser Pro Ala Ala Asn Ala Pro Asp Ala Gly Pro Pro Gln Arg Trp Phe Val Val Trp Leu Gly Thr Ala Asn Asn Pro Val Asp Lys Gly Ala Ala Lys Ala Leu Ala Glu Ser Ile Arg Pro Leu Val Ala Pro Pro Pro Ala Pro Ala Pro Ala Pro Ala Glu Pro Ala Pro Ala Pro Ala Pro Ala Gly Glu Val Ala Pro Thr Pro Thr Thr Pro Thr Pro Gln Arg Thr Leu Pro Ala
SEQ ID No3:
Asp Pro Glu Pro Ala Pro Pro Val Pro Thr Thr Ala Ala Ser Pro Pro Ser Thr Ala Ala Ala Pro Pro Ala Pro Ala Thr Pro Val Ala Pro Pro Pro Pro Ala Ala Ala Asn
Laqueyrerie Anne
Marchal Gilles
Pescher Pascale
Romain Felix
Graser Jennifer E.
Institut Pasteur
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
LandOfFree
Mycobacterial proteins, microorganisms producing them and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mycobacterial proteins, microorganisms producing them and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mycobacterial proteins, microorganisms producing them and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3234320